Identifying the role of Ntrk1 in immunosuppression in Kras/p53 mutant lung cancer
鉴定 Ntrk1 在 Kras/p53 突变肺癌免疫抑制中的作用
基本信息
- 批准号:9906415
- 负责人:
- 金额:$ 7.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-12-09 至 2022-12-08
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenosineBar CodesBlocking AntibodiesCD8-Positive T-LymphocytesCancer EtiologyCancer PatientCell CommunicationCell LineCell SurvivalCell physiologyCellsCessation of lifeChimeric ProteinsClinicClinicalClinical ResearchCollectionCombined Modality TherapyDataDependenceDevelopmentDropoutDrug CombinationsDrug TargetingEpithelialEpitheliumFDA approvedFlow CytometryFunctional disorderGenesGeneticGenetic EngineeringGoalsGrowthHumanImageImmuneImmune System DiseasesImmune checkpoint inhibitorImmune systemImmunocompetentImmunomodulatorsImmunosuppressionImmunotherapyImplantInflammatoryInterleukin-10KRAS2 geneLibrariesLung NeoplasmsLung diseasesMAP Kinase GeneMalignant NeoplasmsMalignant neoplasm of lungMesenchymalMesenchymal Cell NeoplasmMessenger RNAMinorityMusMutationNeoplasm MetastasisNeuronsNon-Small-Cell Lung CarcinomaOutcomePD-1 blockadePD-1 inhibitorsPD-1/PD-L1PDL1 inhibitorsPathway interactionsPatient-Focused OutcomesPatientsPhenotypePhosphotransferasesPopulationPre-Clinical ModelProtein Tyrosine KinaseProteinsProto-Oncogene Proteins c-aktReceptor Protein-Tyrosine KinasesResistanceResistance developmentRoleSignal TransductionSolid NeoplasmSplenocyteSurvival RateT-LymphocyteTP53 geneTestingTherapeuticTimeTissue SampleTranscriptTranscriptional ActivationUnited StatesUp-RegulationWomanWorkanti-PD1 antibodiesbasecancer cellcancer immunotherapeuticscancer typecheckpoint inhibitionclinical applicationclinically relevantcytokineexhaustexhaustiongenetic signaturegenomic profilesimmune checkpoint blockadeimmune system functionimprovedimproved outcomein vivoinhibitor/antagonistknock-downmenmigrationmutantneoplastic cellnoveloutcome forecastoverexpressionpatient responsepre-clinicalpressureprogrammed cell death ligand 1programmed cell death protein 1receptorresistance mechanismresponsesmall hairpin RNAtargeted treatmenttooltreatment strategytumortumor growthtumor progressiontumor-immune system interactions
项目摘要
Project Summary
Lung cancer is the leading cause of cancer-related deaths in the United States, and the 5-year survival rate of
all lung cancer patients combined is only about 18%. The implementation of cancer immunotherapeutics for solid
tumors such as lung cancers has shown great promise and provided the possibility for improved outcome in a
small percentage of patients. However, the majority of patients show little to no response or acquire resistance
during treatment with checkpoint inhibitors delivered as a monotherapy. Therefore, identifying resistance
mechanisms and potential combination therapy approaches is a critical need to improve response rates to
immune checkpoint inhibitors and patient prognosis. To address this, a clinically relevant in vivo shRNA dropout
screen focused on genes encoding for FDA-approved drug targets (FDAome) was performed in epithelial and
mesenchymal Kras/p53 (KP) mutant murine lung cancer cells. Mice were then treated with either isotype or anti-
PD-1 antibody. Sequencing for the barcoded shRNAs revealed that Ntrk1 was significantly depleted from
mesenchymal tumors challenged with PD-1 blockade compared to isotype treated tumors, suggesting it provides
a survival advantage to these tumor cells when under immune system pressure. Preliminary data confirmed
Ntrk1 transcript levels are upregulated in mesenchymal tumors treated with PD-1 inhibitors and cell lines derived
from resistant tumors, and analysis of human NSCLC cell lines revealed that Ntrk1 mRNA levels correlate with
a more aggressive, mesenchymal cell phenotype. Additionally, Ntrk1 overexpressing cells upregulate PD-L1
expression when co-cultured with splenocytes through upregulation of JAK signaling. Stable knockdown of Ntrk1
in mesenchymal murine KP mutant lung cancer cells reduced tumor growth in vivo and analysis of tumor-
infiltrating T cell populations via flow cytometry showed that CD8+ T cell exhaustion was significantly reduced,
whereas overexpression of Ntrk1 promoted CD8+ T cell exhaustion, thus decreasing effector status. These
tumors also have an altered microenvironment, with upregulation of classically immunosuppressive cytokines
such as IL-10. PD-1 protein levels were also significantly increased in Ntrk1-high human NSCLC cell lines,
providing additional evidence that Ntrk1 may be a modulator of immune system functionality in human lung
disease. The central hypothesis of the proposed work is that Ntrk1 upregulation causes acquired resistance to
PD-1 blockade via aberrant JAK signaling and downstream CD8+ T cell dysfunction, thereby promoting tumor
cell survival. A variety of powerful tools will be utilized to test this hypothesis, including time-lapse imaging of
dynamic T cell-tumor cell interactions, genetically-engineered and syngeneic preclinical models of lung cancer
to analyze immune subpopulations as a function of Ntrk1 expression, and IHC analyses of human NSCLC tissue
samples. The goal of the proposed work is to provide strong evidence for a rational drug combination of Ntrk1
inhibitors with PD-1 blockade to be carried forward into the clinic to abrogate immune checkpoint blockade
resistance and ultimately improve patient outcomes.
项目摘要
肺癌是美国癌症相关死亡的主要原因,
所有肺癌患者加起来只有大约18%。癌症免疫治疗的实施对于固体
肿瘤如肺癌已经显示出很大的希望,并提供了改善预后的可能性,
小部分患者。然而,大多数患者几乎没有反应或获得耐药性
在作为单一疗法递送的检查点抑制剂治疗期间。因此,鉴定耐药性
机制和潜在的联合治疗方法是一个关键的需要,以提高反应率,
免疫检查点抑制剂和患者预后。为了解决这个问题,临床相关的体内shRNA缺失
在上皮细胞中进行集中于编码FDA批准的药物靶点(FDAome)的基因的筛选,
间充质Kras/p53(KP)突变小鼠肺癌细胞。然后用同种型或抗-
PD-1抗体。对条形码化的shRNA进行测序显示,Ntrk 1从
与同种型治疗的肿瘤相比,用PD-1阻断剂攻击的间充质肿瘤,表明它提供了
在免疫系统压力下,这些肿瘤细胞的生存优势。初步数据证实
在用PD-1抑制剂处理的间充质肿瘤中Ntrk 1转录水平上调,
对人NSCLC细胞系的分析显示,Ntrk 1 mRNA水平与
更具侵略性的间充质细胞表型此外,Ntrk 1过表达细胞上调PD-L1
当与脾细胞共培养时,通过上调JAK信号传导表达。Ntrk 1的稳定敲除
在间充质鼠KP突变肺癌细胞中减少体内肿瘤生长和分析肿瘤-
通过流式细胞术的浸润T细胞群显示CD 8 + T细胞耗竭显著降低,
而Ntrk 1的过表达促进CD 8 + T细胞耗竭,从而降低效应子状态。这些
肿瘤还具有改变的微环境,具有经典免疫抑制细胞因子的上调
例如IL-10。PD-1蛋白水平在Ntrk 1高人NSCLC细胞系中也显著增加,
提供了Ntrk 1可能是人肺中免疫系统功能的调节剂的额外证据
疾病拟议工作的中心假设是Ntrk 1上调导致对抗结核病的获得性抵抗。
通过异常JAK信号传导和下游CD 8 + T细胞功能障碍阻断PD-1,从而促进肿瘤
细胞存活各种强大的工具将被用来测试这一假设,包括时间推移成像的
动态T细胞-肿瘤细胞相互作用、肺癌的基因工程和同基因临床前模型
分析作为Ntrk 1表达函数的免疫亚群,以及人NSCLC组织的IHC分析
样品这项工作的目的是为Ntrk 1的合理药物组合提供强有力的证据。
将PD-1阻断剂用于临床,以消除免疫检查点阻断
并最终改善患者的预后。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jessica Konen其他文献
Jessica Konen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jessica Konen', 18)}}的其他基金
Identifying the role of Ntrk1 in immunosuppression in Kras/p53 mutant lung cancer
鉴定 Ntrk1 在 Kras/p53 突变肺癌免疫抑制中的作用
- 批准号:
10304891 - 财政年份:2019
- 资助金额:
$ 7.01万 - 项目类别:
Defining an LKB1-regulated motility switch in cancer cell invasion and metastasis
定义癌细胞侵袭和转移中 LKB1 调节的运动开关
- 批准号:
8717302 - 财政年份:2014
- 资助金额:
$ 7.01万 - 项目类别:
Defining an LKB1-regulated motility switch in cancer cell invasion and metastasis
定义癌细胞侵袭和转移中 LKB1 调节的运动开关
- 批准号:
9064098 - 财政年份:2014
- 资助金额:
$ 7.01万 - 项目类别:
Defining an LKB1-regulated motility switch in cancer cell invasion and metastasis
定义癌细胞侵袭和转移中 LKB1 调节的运动开关
- 批准号:
8892799 - 财政年份:2014
- 资助金额:
$ 7.01万 - 项目类别:
相似国自然基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
- 批准号:82074359
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
- 批准号:81570244
- 批准年份:2015
- 资助金额:57.0 万元
- 项目类别:面上项目
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
- 批准号:81171113
- 批准年份:2011
- 资助金额:55.0 万元
- 项目类别:面上项目
相似海外基金
Targeting the A2B Adenosine Receptor for Immunoprevention of Pancreatic Cancer
靶向 A2B 腺苷受体用于胰腺癌的免疫预防
- 批准号:
10929664 - 财政年份:2023
- 资助金额:
$ 7.01万 - 项目类别:
Exploring the role of adenosine A2A receptors in Schizophrenia using opto-pharmacologically controlled allosteric modulation.
利用光药理学控制的变构调节探索腺苷 A2A 受体在精神分裂症中的作用。
- 批准号:
23K14685 - 财政年份:2023
- 资助金额:
$ 7.01万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Role of Adenosine Kinase in Mixed Diastolic Heart Failure and Alzheimer Disease
腺苷激酶在混合性舒张性心力衰竭和阿尔茨海默病中的作用
- 批准号:
10679989 - 财政年份:2023
- 资助金额:
$ 7.01万 - 项目类别:
Allostery-driven G protein selectivity in the adenosine A1 receptor
腺苷 A1 受体中变构驱动的 G 蛋白选择性
- 批准号:
BB/W016974/1 - 财政年份:2023
- 资助金额:
$ 7.01万 - 项目类别:
Research Grant
Investigation of new test methods for adenosine-sensitive atrioventricular block
腺苷敏感型房室传导阻滞新检测方法的探讨
- 批准号:
23K07566 - 财政年份:2023
- 资助金额:
$ 7.01万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing the role of adenosine pathway in SIV pathogenesis
探讨腺苷途径在 SIV 发病机制中的作用
- 批准号:
10760676 - 财政年份:2023
- 资助金额:
$ 7.01万 - 项目类别:
The role of A1 adenosine receptor signaling in the decline of S. pneumoniae killing by neutrophils in vaccinated aged hosts
A1 腺苷受体信号传导在疫苗接种老年宿主中中性粒细胞杀伤肺炎链球菌下降中的作用
- 批准号:
10605737 - 财政年份:2023
- 资助金额:
$ 7.01万 - 项目类别:
Adenosine triphosphate as a master variable for biomass in the oceanographic context
三磷酸腺苷作为海洋学背景下生物量的主变量
- 批准号:
2319114 - 财政年份:2023
- 资助金额:
$ 7.01万 - 项目类别:
Standard Grant
Late-Stage Functionalisation of Cyclic Guanosine Monophosphate - Adenosine Monophosphate
环单磷酸鸟苷-单磷酸腺苷的后期功能化
- 批准号:
2751533 - 财政年份:2022
- 资助金额:
$ 7.01万 - 项目类别:
Studentship
Postnatal development of adenosine kinase in the brainstem network that controls breathing
控制呼吸的脑干网络中腺苷激酶的出生后发育
- 批准号:
573323-2022 - 财政年份:2022
- 资助金额:
$ 7.01万 - 项目类别:
University Undergraduate Student Research Awards